GoodRx (GDRX)
(Delayed Data from NSDQ)
$7.10 USD
-0.05 (-0.70%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $7.10 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GDRX 7.10 -0.05(-0.70%)
Will GDRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GDRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GDRX
Is GoodRx (GDRX) Outperforming Other Medical Stocks This Year?
ELV vs. GDRX: Which Stock Is the Better Value Option?
GDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ELV or GDRX: Which Is the Better Value Stock Right Now?
Wall Street Analysts Predict a 29.1% Upside in GoodRx Holdings, Inc. (GDRX): Here's What You Should Know
Encompass Health (EHC), Piedmont to Build Loganville Facility
Other News for GDRX
Investors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky LLP Before June 21, 2024 to Discuss Your Rights – GDRX
GoodRx Announces Date for 2024 Investor Day
NCPDP Foundation Funds New Project to Streamline REMS Process for the Industry
NCPDP's National Facilitator Model Pilot Project Enters Second Phase
Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)